Free Trial
NASDAQ:ERAS

Erasca (ERAS) Stock Price, News & Analysis

Erasca logo
$1.43 -0.17 (-10.63%)
Closing price 09/3/2025 04:00 PM Eastern
Extended Trading
$1.41 -0.02 (-1.40%)
As of 05:54 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Erasca Stock (NASDAQ:ERAS)

Key Stats

Today's Range
$1.33
$1.49
50-Day Range
$1.26
$1.74
52-Week Range
$1.01
$3.31
Volume
2.86 million shs
Average Volume
641,381 shs
Market Capitalization
$405.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.71
Consensus Rating
Moderate Buy

Company Overview

Erasca Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

ERAS MarketRank™: 

Erasca scored higher than 47% of companies evaluated by MarketBeat, and ranked 594th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Erasca has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Erasca has only been the subject of 2 research reports in the past 90 days.

  • Read more about Erasca's stock forecast and price target.
  • Earnings Growth

    Earnings for Erasca are expected to grow in the coming year, from ($0.73) to ($0.61) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Erasca is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Erasca is -3.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Erasca has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Erasca's valuation and earnings.
  • Percentage of Shares Shorted

    11.69% of the float of Erasca has been sold short.
  • Short Interest Ratio / Days to Cover

    Erasca has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Erasca has recently decreased by 1.31%, indicating that investor sentiment is improving.
  • Dividend Yield

    Erasca does not currently pay a dividend.

  • Dividend Growth

    Erasca does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.69% of the float of Erasca has been sold short.
  • Short Interest Ratio / Days to Cover

    Erasca has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Erasca has recently decreased by 1.31%, indicating that investor sentiment is improving.
  • News Sentiment

    Erasca has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Erasca this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for ERAS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Erasca insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    14.40% of the stock of Erasca is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    67.78% of the stock of Erasca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Erasca's insider trading history.
Receive ERAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Erasca and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ERAS Stock News Headlines

Erasca double downgraded to Underperform at BofA
Elon’s Secret Social Security Bombshell
To All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.tc pixel
Erasca (NASDAQ:ERAS) Upgraded to Hold at Wall Street Zen
Erasca (NASDAQ:ERAS) Rating Lowered to "Sell" at Wall Street Zen
Morgan Stanley Downgrades Erasca (ERAS)
See More Headlines

ERAS Stock Analysis - Frequently Asked Questions

Erasca's stock was trading at $2.51 at the beginning of 2025. Since then, ERAS shares have decreased by 43.0% and is now trading at $1.43.

Erasca, Inc. (NASDAQ:ERAS) announced its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.12).

Erasca (ERAS) raised $262 million in an initial public offering (IPO) on Thursday, July 15th 2021. The company issued 17,500,000 shares at $14.00-$16.00 per share.

Erasca's top institutional investors include Frazier Life Sciences Management L.P. (8.01%), VR Adviser LLC (6.30%), Geode Capital Management LLC (1.71%) and Affinity Asset Advisors LLC (1.44%). Insiders that own company stock include Jonathan E Lim, Bihua Chen, Alexander W Casdin and Valerie Denise Harding Start.
View institutional ownership trends
.

Shares of ERAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Erasca investors own include Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY), American Water Works (AWK), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM).

Company Calendar

Last Earnings
8/12/2025
Today
9/04/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ERAS
CIK
1761918
Fax
N/A
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$6.00
Low Price Target
$1.00
Potential Upside/Downside
+159.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$161.65 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-31.19%
Return on Assets
-26.34%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.03
Quick Ratio
11.04

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.31 per share
Price / Book
1.09

Miscellaneous

Outstanding Shares
283,670,000
Free Float
242,822,000
Market Cap
$405.65 million
Optionable
Optionable
Beta
1.08

Social Links

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ERAS) was last updated on 9/4/2025 by MarketBeat.com Staff
From Our Partners